title: Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
authors.affiliation: Addenbrooke's Hospital, Cambridge, UK. bcsh@b-s-h.org.uk
authors.forename: Trevor
authors.initials: T
authors.lastname: Baglin
authors.forename: David
authors.initials: D
authors.lastname: Keeling
authors.forename: Steve
authors.initials: S
authors.lastname: Kitchen
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000379:methods* / Q000592:standards*; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment / Q000379:methods; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran